| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology |
Recent Updates
Recently added Catalysts
Krystal Biotech, Inc.$351.82
+16.63 (+4.96%)
C 48Pipeline Score Richly Valued Biotech · Commercial
Market Cap
8.83 B
EPS
7.74
P/E Ratio
40.03 $
Value Trade
72.18 M
SEC Financials
Q1 2026Dilution Risk
Revenue
116.36 M
R&D Expenses
15.33 M
Operating CF
80.38 M
Total Assets
1.40 B
Total Liabilities
120.24 M
Equity
1.28 B
D/E Ratio
12,345
-4.11 %
Week
8.82 %
1 Month
14.51 %
3 Month
46.75 %
6 Month
337.03 %
5 Year
2,751.9 %
All Time
Cash Data
Cash Position
823.40 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
537.30 K
52 Week Range
123.03 - 319.48
% held by Insiders
12.56 %
% held by Institutions
96.39 %
Enterprise Value
8.01 B
Total Shares
29.48 M
Short %
15.17 %
Float Shares
23.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Krystal Biotech, Inc.
734Total events
19Upcoming
133Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Poster PresentationKB707Presentation
Subscribe to view catalyst details
TBD
◆Oral PresentationKB407FiledPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-10-31 | KB707 (redosable immunotherapy) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2025-10-31 | KB707 (redosable immunotherapy) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2025-10-31 | KB707 (redosable immunotherapy) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
Drug Pipeline Intelligence
C48
Pipeline Score $25M
Pipeline ValueRichly Valued
Valuation Signal9
Drugs Scored0.0x
rNPV / MCap Top 75%
Small Cap (rank 229 of 913)
Percentile RankKrystal Biotech, Inc. carries a moderate pipeline score (48/100), with $39M risk-adjusted pipeline value, led by KB707 in Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KB707 Monoclonal antibody | Cancer | Phase 1 | NCT05970497 | 12% | $39M | RECRUITING | 240 | STALLED | D (37) | Jul 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KB407 Orphan | Cystic Fibrosis | Phase 1 | 2026-01-09 | transduction rate range: 29.4% to 42.1%; patients dosed: 7; successful bronchoscopies: 6 Read More | Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Read More | |
KB407 Orphan | Cystic Fibrosis | Phase 1 | 2026-01-09 | transduction rate range: 29.4% to 42.1%; patients dosed: 7; successful bronchoscopies: 6 Read More | Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Read More | |
KB407 Orphan | Cystic Fibrosis | Phase 1 | 2026-01-09 | transduction rate range: 29.4% to 42.1%; patients dosed: 7; successful bronchoscopies: 6 Read More | Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KRYS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KRYS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KRYSKrystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Krystal Biotech, Inc. announced it will report its second quarter 2026 financial results on August 3, 2026. A conference call and webcast will follow at 8:30 am ET to discuss the results and provide a business update. Investors can access the live event and a subsequent replay on the company's website.
Read more →KRYSKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced that its gene therapy, VYJUVEK, received marketing authorization from the UK's MHRA for treating dystrophic epidermolysis bullosa (DEB) from birth. This marks VYJUVEK as the first genetic medicine approved in the UK for this condition. The therapy aims to address the root cause of DEB by delivering functional copies of the COL7A1 gene, ensuring effective wound healing. Following approvals in the US, EU, and Japan, the company looks to ensure broad access for patients in the UK.
Read more →KRYSKrystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech, Inc. will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. CEO Krish S. Krishnan will participate in a fireside chat and host investor meetings. The event underscores the company's commitment to advancing genetic medicines, including its first product, VYJUVEK®, approved for dystrophic epidermolysis bullosa.
Read more →KRYS▲ +7.9%on this newsshared move
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Krystal Biotech reported strong financial results for Q1 2026, with VYJUVEK generating $116.4 million in revenue, a 32% increase from the previous year. The company has completed enrollment in its registrational study for KB803 and is on track for data readouts in 2026. Additionally, the FDA granted platform technology designation for KB407 and KB111, enhancing regulatory advantages for these products. The company maintains a robust cash position of $1.0 billion.
Read more →KRYSKrystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech, Inc. will present at several upcoming scientific conferences in May and June 2026. Key presentations include evaluations of gene therapy vectors for primary ciliary dyskinesia and interim results from a cystic fibrosis trial. The company's innovative approaches to genetic medicine are showcased at these events.
Read more →KRYSKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Krystal Biotech, Inc. will report its first quarter 2026 financial results on May 4, 2026. The announcement includes a conference call and webcast at 8:30 am ET to discuss the results and provide a business update. Investors can access the live webcast online, with a replay available for 30 days.
Read more →KRYSKrystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Krystal Biotech, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. The company will participate in a fireside chat and hold investor meetings throughout the day. A webcast of the presentation will be available on their website.
Read more →KRYSKrystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Krystal Biotech reported strong financial results for Q4 and the full year 2025, with $107.1 million in revenue from VYJUVEK. The company received FDA designations for its treatments KB707 and KB111, enhancing its pipeline for rare diseases. With a solid cash position of $955.9 million, Krystal is poised for future growth and product launches.
Read more →KRYSDocument Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment o
Krystal Biotech reported impressive financial results for Q4 and full year 2025, with a significant revenue increase from VYJUVEK and notable regulatory progress. The company's VYJUVEK net product revenue reached $107.1 million in Q4 and $389.1 million for the year, reflecting strong demand and a solid market presence. Furthermore, the FDA granted RMAT designation to KB707 for advanced non-small cell lung cancer, highlighting advancements in their pipeline. However, ongoing pricing negotiations in Europe and Italy could impact future sales and product availability.
Read more →KRYSKrystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026. The company will also host a conference call and webcast to discuss these results and provide a business update. Investors can access the live webcast and a replay will be available for 30 days on the company's website.
Read more →KRYSKrystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Krystal Biotech has received RMAT designation from the FDA for KB707, an immunotherapy aimed at treating advanced or metastatic non-small cell lung cancer (NSCLC). This designation highlights the urgent need for new therapies in NSCLC and is supported by promising early clinical data from the ongoing KYANITE-1 study. The RMAT designation will facilitate accelerated development and potential approval processes for KB707.
Read more →KRYSKrystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. has announced preliminary unaudited financial results for 2025, projecting net product revenue for VYJUVEK between $106 million and $107 million for the fourth quarter. The company outlined its strategic vision for growth in rare diseases, emphasizing a strong clinical pipeline and significant cash reserves of approximately $955 million. With plans to launch additional therapies and expand its reach, Krystal aims to have at least four marketed rare disease medicines by 2030. The announcement coincides with their upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Read more →KRYS▲ +5%on this news· ran to +17% by day 3shared move
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Krystal Biotech announced positive interim results from its Phase 1 CORAL-1 study of KB407, confirming successful delivery of wild-type CFTR protein in patients with cystic fibrosis. The study demonstrated high transduction rates across diverse patient backgrounds. The company plans to initiate the registrational CORAL-3 study in 2026, aiming to evaluate repeat dosing of KB407.
Read more →KRYSKrystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Krystal Biotech, Inc. announced it will hold an investor conference call on January 8, 2026, to provide an interim update from its Phase 1 CORAL-1 study evaluating KB407 for cystic fibrosis. The update will focus on molecular assessments related to KB407 transduction and CFTR protein expression in patients receiving the highest dose. This follows the company's ongoing commitment to develop genetic medicines for unmet medical needs.
Read more →KRYSKrystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Krish S. Krishnan will lead the presentation at 10:30 am ET and host investor meetings throughout the day. The event highlights the company's commitment to advancing genetic medicines for unmet medical needs.
Read more →KRYSKrystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Krystal Biotech, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. CEO Krish S. Krishnan will participate in a fireside chat and host investor meetings. A webcast of the presentation will be available on the company's website, promoting transparency with investors.
Read more →KRYSKrystal Biotech Announces Third Quarter 2025 Financial and Operating Results
Krystal Biotech reported a strong financial performance for Q3 2025, with VYJUVEK generating $97.8 million in revenue. The company launched VYJUVEK in Germany and plans further launches in France and Japan. An updated U.S. label for VYJUVEK has expanded the eligible patient population. The company is well-positioned for future growth with a robust pipeline and significant cash reserves.
Read more →KRYSDocument Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results $97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q launched in France and Japa
Krystal Biotech reported strong third quarter results for 2025, highlighting $97.8 million in revenue from VYJUVEK, totaling $623.2 million since its U.S. launch. The company successfully expanded VYJUVEK's market reach with recent launches in Germany, France, and Japan, and received FDA approval for a label update that broadens the eligible patient population. Additionally, the firm holds $864.2 million in cash, positioning it well for future growth. Upcoming clinical data for cystic fibrosis treatment KB407 is expected in Q4 2025.
Read more →KRYSKrystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
Krystal Biotech, Inc. (NASDAQ: KRYS) announced that it will report its third quarter 2025 financial results on November 3, 2025, before the U.S. markets open. The company will also host a conference call and webcast to discuss these results and provide a business update at 8:30 am ET on the same day. Investors can access the live webcast and will have the option to view a replay for up to 30 days. Krystal Biotech continues to expand its portfolio, with a focus on genetic medicines.
Read more →KRYSKrystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
Krystal Biotech has received FDA platform technology designation for its HSV-1 viral vector used in KB801, a gene therapy for neurotrophic keratitis. This designation may streamline drug development and regulatory processes, leveraging prior data from FDA-approved products. The company aims to enhance treatment efficiency for patients suffering from this rare corneal disease.
Read more →KRYS▲ +8.4%on this news
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Krystal Biotech announced that the FDA has approved an updated label for VYJUVEK, allowing treatment for dystrophic epidermolysis bullosa (DEB) patients from birth. The update enables patients and caregivers to apply the treatment at home, enhancing convenience and compliance. Additionally, it allows for more flexible management of wound dressings, reinforcing VYJUVEK's role as a standard of care for DEB.
Read more →KRYSKrystal Biotech to Present at Cantor Global Healthcare Conference 2025
Krystal Biotech, Inc. will present at the Cantor Global Healthcare Conference 2025 on September 4, 2025. CEO Krish S. Krishnan will participate in a fireside chat and conduct investor meetings. The event highlights the company's commitment to advancing genetic medicines, including its first product, VYJUVEK®, which treats dystrophic epidermolysis bullosa.
Read more →KRYSKrystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
Krystal Biotech has updated its development plans for KB707, focusing on inhaled delivery for treating non-small cell lung cancer (NSCLC). The company received FDA approval for an End of Phase 2 meeting to discuss registration pathways. Promising efficacy data shows a 36% response rate in heavily pre-treated patients, although enrollment in another study has been paused.
Read more →KRYS▼ -14%on this news
Document Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB pat
Krystal Biotech announced its second quarter 2025 financial results, highlighting $96.0 million in VYJUVEK revenues and a total of $525.4 million since the product's launch in Q3 2023. The company reported strong financial health, ending the quarter with $820.8 million in cash. VYJUVEK has received regulatory approval in Japan for treating dystrophic epidermolysis bullosa (DEB) patients from birth, indicating the company's plans for global market expansion. Additionally, the company is progressing in various clinical trials for other therapies, demonstrating its growth potential in the biotech sector.
Read more →KRYS▼ -14%on this news
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
Krystal Biotech reported a strong second quarter for 2025, generating $96 million in revenue from VYJUVEK, which was recently approved in Japan for Dystrophic Epidermolysis Bullosa (DEB) patients. The company highlighted its solid financial standing with $820.8 million in cash. With ongoing clinical trials for several therapies, including KB407, KB408, and KB803, the company is working towards significant advancements in treating various conditions. Furthermore, Krystal aims to launch VYJUVEK in Europe by the end of the year, signaling its commitment to global market expansion.
Read more →KRYSKrystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Krystal Biotech, Inc. has announced it will report its second quarter 2025 financial results on August 4, 2025, prior to the market opening. The company's management will also host a conference call and webcast at 8:30 am ET on the same day to discuss these results and provide a business update. Krystal Biotech is recognized for its innovative gene therapy, VYJUVEK®, which is approved for treating dystrophic epidermolysis bullosa, and the company is actively advancing its pipeline in various medical fields.
Read more →KRYSKrystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced that VYJUVEK has received marketing authorization from Japan's Ministry of Health for treating dystrophic epidermolysis bullosa (DEB) from birth. This marks VYJUVEK as the first genetic medicine approved in Japan for DEB, allowing for home administration. The approval is based on a comprehensive clinical dataset, demonstrating effective wound healing and a favorable safety profile.
Read more →KRYSJeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jeune Aesthetics announced positive results from the Phase 1 PEARL-2 study of KB304, showing significant improvements in wrinkles and skin elasticity. The study demonstrated high satisfaction rates among subjects treated with KB304 compared to placebo. The company plans to advance KB304 into Phase 2 development, targeting the décolletage area, with a meeting scheduled with the FDA to discuss the next steps.
Read more →KRYSKrystal Biotech Announces First Patient Dosed in Phase 1 2 Trial of KB801 for the Treatment of Neurotrophic Keratitis Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the ey
Krystal Biotech has announced the dosing of the first patient in its Phase 1/2 clinical trial, EMERALD-1, for KB801, a gene therapy targeting neurotrophic keratitis (NK). The trial aims to evaluate the safety and efficacy of KB801, delivered via eye drops, which could provide substantial relief for NK patients. The treatment seeks to enable sustained expression of nerve growth factor, thus potentially improving healing outcomes for a rare but serious condition characterized by corneal defects. The company is also working on a Phase 3 study for another treatment in its pipeline.
Read more →KRYSKrystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Krystal Biotech has initiated its Phase 3 clinical trial, IOLITE, for its treatment KB803 aimed at managing corneal abrasions in dystrophic epidermolysis bullosa (DEB) patients, with the first patient dosed. This follows positive outcomes from earlier compassionate use cases, which demonstrated full healing and significant visual acuity improvement in an affected patient. The trial will include approximately 16 subjects, with the primary endpoint evaluating changes in corneal abrasion symptoms versus placebo. The study emphasizes the need for effective therapies in the treatment of ocular complications related to DEB.
Read more →KRYSKrystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Krystal Biotech, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, set for June 10, 2025, in Miami. CEO Krish S. Krishnan will engage in a fireside chat and lead investor meetings throughout the event. The company is noted for its focus on genetic medicines, particularly with its commercial product VYJUVEK® aimed at treating rare diseases. Interested parties can access a webcast of the presentation on the company's website.
Read more →KRYSKrystal Biotech to Present at BofA Securities 2025 Health Care Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. The company's CEO, Krish S. Krishnan, is scheduled to participate in a fireside chat at 11:20 am PT and will hold investor meetings throughout the day. A webcast of the presentation will be made available on the company's website. Krystal Biotech is known for its genetic medicines targeting high unmet medical needs.
Read more →KRYS▼ -14.1%on this newsshared move
Document Krystal Biotech Announces First Quarter 2025 Financial and Operating Results VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since l
Krystal Biotech reported positive financial results for Q1 2025, showcasing $88.2 million in revenue from VYJUVEK, which has been approved in Europe for treating dystrophic epidermolysis bullosa (DEB) patients from birth. The company maintains a robust cash position of $765.3 million and is progressing with new clinical programs, including KB801 for neurotrophic keratitis and ongoing studies for KB407 and KB408. With plans for further clinical readouts in 2025, Krystal Biotech aims to enhance its therapy offerings across various indications.
Read more →KRYS▼ -14.1%on this newsshared move
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
Krystal Biotech reported its financial results for the first quarter of 2025, showcasing an impressive revenue of $88.2 million from VYJUVEK, which was approved for use in Europe. The company ended the quarter with a strong cash position of $765.3 million, facilitating growth and ongoing clinical developments across various therapeutic areas. With further clinical readouts planned for 2025, Krystal is well-positioned to capitalize on its expanding pipeline, which includes therapies for cystic fibrosis and ocular complications of dystrophic epidermolysis bullosa.
Read more →KRYSKrystal Biotech Announces European Commission Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or
Krystal Biotech has received marketing authorization from the European Commission for VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa. This approval allows for the treatment of patients from birth, delivering functional copies of the collagen type VII alpha 1 gene. VYJUVEK can be administered at home or in healthcare settings, catering to patient needs. The first European launch is planned for Germany in mid-2025, following prior FDA approval. Clinical studies supported the decision, showcasing effective gene delivery and wound healing.
Read more →KRYSKrystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
Krystal Biotech, a biotechnology company, will report its first quarter 2025 financial results on May 6, 2025, prior to the U.S. market opening. The management will host a conference call and webcast at 8:30 AM ET the same day to discuss these results and provide a business update. Investors can access the webcast live or listen to a replay available for 30 days on the company's website. Krystal Biotech focuses on genetic medicines for diseases with high unmet needs and is actively developing a pipeline in various therapeutic areas.
Read more →KRYSKrystal Biotech Receives Positive CHMP Opinion for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech has received a positive opinion from the CHMP for VYJUVEK, a gene therapy for patients with dystrophic epidermolysis bullosa (DEB). This therapy is designed to address wounds in patients with COL7A1 mutations and is suitable for administration from birth. The European Commission's final decision is expected in Q2 2025, with potential launches planned in Germany and France. The positive opinion is grounded in strong clinical data demonstrating successful gene delivery and wound closure.
Read more →KRYSKrystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
Krystal Biotech, Inc. has announced its participation in the TD Cowen 45th Annual Health Care Conference scheduled for March 4, 2025, in Boston. CEO Krish S. Krishnan will host a fireside chat and various investor meetings throughout the day. This participation highlights the company's efforts in the biotechnology sector and its focus on developing genetic medicines for various diseases.
Read more →KRYS▲ +12.4%on this news
Document Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473%
Krystal Biotech reported substantial growth in its financial and operational performance for Q4 and full year 2024, with revenues increasing by 116% and 473% respectively. The company highlighted strong sales for its product VYJUVEK, along with major advancements in its clinical trial programs, including significant patient compliance. Despite the positive outlook, the firm is under review for regulatory approvals in various international markets, which poses some risk.
Read more →KRYS▲ +12.4%on this news
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
Krystal Biotech announced impressive financial results for the fourth quarter and full year 2024, with revenues increasing by 116% and 473% respectively. The company reported significant net product revenue from its treatment VYJUVEK for Dystrophic Epidermolysis Bullosa, boasting a high gross margin and strong patient compliance. Additionally, Krystal Biotech is moving forward with multiple clinical programs, including new studies for therapies targeting cystic fibrosis and alpha-1 antitrypsin deficiency. The company ended the quarter with a robust cash position of $749.6 million, ensuring funds for upcoming initiatives.
Read more →KRYSKrystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Krystal Biotech, Inc. has announced that it will report its fourth quarter and full year 2024 financial results on February 19, 2025. This will be followed by a conference call and webcast at 8:30 am ET to discuss the results and provide a business update. Krystal Biotech focuses on developing genetic medicines for diseases with high unmet needs and has successfully launched VYJUVEK®, the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa.
Read more →KRYS▼ -7.3%on this news
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Krystal Biotech announced early clinical results from its KYANITE-1 study, showcasing inhaled KB707's potential as a monotherapy for advanced non-small cell lung cancer (NSCLC). The treatment exhibited a 27% objective response rate and a 73% disease control rate among post-anti-PD-1 NSCLC patients. KB707 was noted to be well tolerated, with mild to moderate treatment-related adverse events. The company plans to expand the study to evaluate KB707 in combination with other therapies as it continues to gather promising data.
Read more →KRYS▼ -7.3%on this news
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
Krystal Biotech has released initial clinical updates for its inhaled genetic medicine programs KB408 and KB407, targeting rare respiratory diseases. Data presented show successful SERPINA1 gene delivery and alpha-1 antitrypsin (AAT) expression in patients with AATD following KB408 administration, with both treatments demonstrating safety and tolerability. The company has planned an investor call for further discussion of these treatment advancements, along with expectations for additional updates in 2025. The ongoing research substantiates the potential of non-invasive therapies for AATD and cystic fibrosis patients.
Read more →KRYSKrystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
Krystal Biotech provided an update on the European Medicines Agency's review of B-VEC for dystrophic epidermolysis bullosa (DEB). The company confirmed there are no major objections to the marketing authorization application. A Committee for Medicinal Products for Human Use (CHMP) opinion is now expected in the first quarter of 2025, with the launch in Germany scheduled for the second quarter of 2025. The company expressed confidence in addressing any outstanding issues to benefit DEB patients.
Read more →KRYSKrystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech, Inc. (NASDAQ: KRYS) announced that its CEO, Krish S. Krishnan, will participate in two investor conferences in early December 2024. He will host fireside chats at Citi’s 2024 Global Healthcare Conference in Miami and the Evercore HealthCONx Conference in Coral Gables. The presentations will be available via live webcasts and archived on the company’s website. Krystal Biotech is focused on developing genetic medicines, with a strong pipeline aimed at treating diseases with significant unmet medical needs.
Read more →KRYSKrystal Biotech to Present at Stifel 2024 Healthcare Conference
Krystal Biotech, Inc. will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. CEO Krish S. Krishnan is scheduled to take part in a fireside chat and host investor meetings. The event highlights the company's efforts to engage with investors as it advances its portfolio of genetic medicines, including its first product for treating dystrophic epidermolysis bullosa.
Read more →KRYSKrystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Biotech, Inc. will present at the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. CEO Krish S. Krishnan is scheduled to participate in a fireside chat and conduct investor meetings throughout the day. A webcast of the presentation will be available for interested parties. The company focuses on developing genetic medicines for conditions with significant unmet medical needs.
Read more →KRYSDocument Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on
Krystal Biotech announced its third quarter 2024 financial results, revealing a net product revenue of $83.8 million since the launch of VYJUVEK in August 2023. The company filed a Japan New Drug Application for B-VEC and received early access approval in France. Additionally, it advanced its KB301 treatment to Phase 2 after successful outcomes in Phase 1. With a robust cash position of $694.2 million, Krystal Biotech remains on track for further commercial launches in Europe and Japan in 2025.
Read more →KRYSKrystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
Krystal Biotech reported favorable financial results and business updates for Q3 2024, highlighting a net product revenue of $83.8 million and total revenue of $250.1 million since launch. The company has filed for commercial launch approvals in Japan and Europe for its treatment B-VEC, with early access already granted in France for DEB patients. Additionally, it advanced the KB301 product to Phase 2 after positive initial results. Overall, Krystal's financial standing remains robust, with significant cash reserves to support ongoing projects.
Read more →KRYSKrystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
Krystal Biotech, Inc. will report its third quarter financial results on November 4, 2024, before U.S. markets open. A conference call and webcast will be held at 8:30 am ET the same day to discuss the results and provide updates on the business. The company, which focuses on developing genetic medicines for unmet medical needs, is known for its FDA-approved product VYJUVEK® and has a promising pipeline in various therapeutic areas.
Read more →KRYSKrystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) announced its participation in the 2024 Cantor Global Healthcare Conference scheduled for September 18, 2024. CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings. The presentation will be broadcasted via a webcast accessible from the company's website. Krystal Biotech is noted for its pioneering work in genetic medicines, including VYJUVEK®, the first FDA-approved treatment for dystrophic epidermolysis bullosa.
Read more →KRYSKrystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
Krystal Biotech, Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. CEO Krish S. Krishnan is set to present and host investor meetings, enhancing the company’s outreach to potential investors. The event underscores Krystal Biotech's active role in the biotechnology sector, especially in genetic medicine development. A webcast of the presentation will be available for interested parties.
Read more →KRYSSubjects also reported improvements in wrinkles that increased from the first to second follow up month, as assessed by GAIS: o At two months: 89% of subjects reported at least a one point improvement and 39% reported a
Jeune Aesthetics announced positive interim results from its Phase 1 study evaluating KB301 for treating lateral canthal lines and dynamic wrinkles. The study reported significant improvements in wrinkle appearance, with a majority of subjects expressing satisfaction with results two months post-treatment. KB301 leverages Krystal's gene-delivery technology to enhance collagen levels in the skin. The results indicate a potential paradigm shift in aesthetic treatments, paving the way for the Phase 2 study expected to commence next year.
Read more →KRYS▼ -5.9%on this news
Document Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three c
Krystal Biotech has reported robust financial results for Q2 2024, with net product revenue reaching $70.3 million, marking a 55.3% increase from the previous quarter. The company is on track to deliver three important clinical readouts in the second half of 2024 across its pipeline of genetic therapies. With a strong cash position of $628.9 million, Krystal is well-positioned to advance its operational plans and market expansions. Additionally, patient compliance remains high at 90%, indicating strong demand for their therapies.
Read more →KRYS▼ -5.9%on this news
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
Krystal Biotech, Inc. (NASDAQ: KRYS) reported a strong financial performance in the second quarter of 2024, with net product revenue for VYJUVEK reaching $70.3 million, marking a 55.3% increase from the previous quarter. The company has a strong financial position with $628.9 million in cash and investments. Additionally, Krystal plans to deliver three important clinical readouts in the second half of 2024. The CEO highlighted sustained demand for VYJUVEK and favorable reimbursement approvals as key drivers of growth.
Read more →KRYSKrystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
Krystal Biotech, Inc. has announced it will report its second quarter 2024 financial results on August 5, 2024, before the stock market opens. The company's management will follow this announcement with a conference call and webcast to discuss the results and provide updates on the business. Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines, with its first product, VYJUVEK®, already making strides in the market.
Read more →KRYSKrystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan is scheduled for a fireside chat at 10:40 am ET and will meet with investors throughout the conference. This participation highlights the company's commitment to engaging with the investment community while promoting its innovative genetic medicines aimed at addressing significant medical needs.
Read more →KRYSKrystal Biotech to Present at the American Thoracic Society 2024 International Conference
Krystal Biotech, Inc. will present new preclinical data on their respiratory genetic medicine candidates, KB407 and KB408, at the American Thoracic Society 2024 International Conference from May 17-22 in San Diego. Both candidates are being evaluated in Phase 1 studies for the treatment of cystic fibrosis and alpha-1 antitrypsin deficiency, respectively. The presentations will include details on KB407's efficacy in patient-derived models and ongoing studies supporting KB408's development. Following the conference, the posters will be available online.
Read more →KRYSKrystal Biotech to Present at BofA Securities 2024 Health Care Conference
Krystal Biotech, Inc. announced its participation in the BofA Securities 2024 Health Care Conference, scheduled for May 14, 2024, in Las Vegas. CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings throughout the day. This event represents an opportunity for the company to present its advancements in genetic medicine and discuss its commercial product, VYJUVEK®, among potential investors.
Read more →KRYSKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locall
Krystal Biotech reported strong financial results for the first quarter of 2024, with net product revenue reaching $45.3 million. The company also announced the dosing of the first patient in a study for inhaled KB707, aimed at treating locally advanced lung tumors. Krystal's key therapies continue to receive regulatory designations, including Fast Track status for KB707. Additionally, VYJUVEK is experiencing strong growth in the U.S. market with high patient compliance and robust reimbursement approvals.
Read more →KRYSKrystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Krystal Biotech, Inc. will present new preclinical data on its HSV-1 based vector platform for back of the eye gene delivery at the ARVO 2024 Annual Meeting in Seattle from May 5-9, 2024. The poster presentation, titled 'An HSV-1-Based Vector Platform for Localized Delivery to the Posterior of the Eye,' will take place on May 7, 2024. The event underscores the company's commitment to advancing genetic medicines aimed at addressing significant medical needs.
Read more →KRYSKrystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
Krystal Biotech, Inc. announced that it will report its first quarter 2024 financial results on May 6, 2024, before U.S. market opening. The company will host a conference call and webcast to discuss the financial results and provide updates on its business. The webcast will be accessible to the public and a replay will be available for 30 days afterward.
Read more →KRYSKrystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Krystal Biotech announced the dosing of the first patient in its Phase 1 clinical trial, KYANITE-1, for inhaled KB707 targeting advanced lung tumors. KB707 is a modified HSV-1 vector intended to deliver therapeutic genes for immunotherapy directly to tumors. The trial aims to evaluate its efficacy as a novel treatment option for solid tumors that are hard to treat. The FDA has granted Fast Track Designation to expedite the drug's development in addressing serious conditions in lung cancer patients.
Read more →KRYSKrystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Krystal Biotech, Inc. announced its participation in the AACR 2024 Annual Meeting, where it will present preclinical data on its innovative technology that uses an HSV-1-based vector to deliver immune-modulating cytokines IL-12 and IL-2 for cancer therapy. The presentation, scheduled for April 10, 2024, could impact tumor treatment strategies by potentially reshaping immune responses. This event showcases the company's advancements in genetic medicines and its commitment to addressing high unmet medical needs in oncology.
Read more →KRYSKrystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) will present at the TD Cowen 44th Annual Health Care Conference in Boston from March 4-6, 2024. CEO Krish S. Krishnan is set to participate in a fireside chat at 9:50 am ET and will hold investor meetings the following day. A webcast of the presentation will be available on the company's Investor section online. Krystal Biotech is focused on developing genetic medicines, including its first commercial product, VYJUVEK®, aimed at treating dystrophic epidermolysis bullosa.
Read more →KRYS▲ +41%on this news· ran to +53% by day 1shared move
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Krystal Biotech reported significant financial results for Q4 and full year 2023, with net product revenue of $42.1 million in Q4 and $50.7 million for the year, primarily from sales of VYJUVEK. The company also announced successful alignment with the FDA to advance its B-VEC eyedrop formulation for treating ocular complications in DEB patients. Additionally, the first patient has been dosed in the Phase 1 KB408 trial for AATD, and a strong cash position of $594.1 million supports ongoing and future clinical trials. Overall, the company is well-positioned for growth in its innovative gene therapy pipeline.
Read more →KRYS▲ +41%on this news· ran to +53% by day 1shared move
Years Ended December 31, (in thousands, except shares and per share data) 2023 2022 Change Revenue Product revenue, net $ 50,699 $ - $ 50,699 Expenses Cost of goods sold 3,094 - 3,094 Research and development 46,431 42,4
Krystal Biotech announced its financial results for Q4 and the full year 2023, showcasing a strong net product revenue of $50.7 million from VYJUVEK. The company has achieved FDA alignment for B-VEC eyedrop formulation and initiated multiple clinical trials, including the first patient dosed in the KB408 trial for AATD. The approval and commercial launch of VYJUVEK marks a pivotal moment for the company. Financially, Krystal maintains a robust position with $594.1 million in cash, enabling continued clinical development and market expansion efforts.
Read more →KRYSKrystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Krystal Biotech, Inc. (NASDAQ: KRYS) is set to announce its fourth quarter and full year 2023 financial results on February 26, 2024, before U.S. markets open. Following the report, a webcast will be held at 8:30 am ET to discuss the results and provide a business update. The company is known for its innovative genetic medicines, including VYJUVEK, which addresses high unmet medical needs in dermatological conditions.
Read more →KRYS▼ -6.2%on this news
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
Krystal Biotech has received FDA Fast Track Designation for its inhaled oncology candidate KB707, aimed at treating solid tumors with pulmonary metastases that are resistant to existing therapies. This designation reflects the urgent medical need for effective treatments for such patients, as many existing options are limited or non-existent. The company plans to initiate a Phase 1 clinical trial in the first half of 2024, emphasizing the promising nature of cytokine therapy and its specific targeting of lung tumors. KB707 is designed to directly deliver genes encoding for interleukin-12 and interleukin-2, potentially improving immune responses against tumors.
Read more →KRYSKrystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
Krystal Biotech announced the publication of data in the New England Journal of Medicine regarding the use of B-VEC for treating ocular complications in a patient with dystrophic epidermolysis bullosa (DEB). The study reports significant improvements in the patient's visual acuity and complete corneal healing after the administration of B-VEC eyedrops. This publication marks the second time B-VEC clinical data has appeared in NEJM, reinforcing the therapy's promise for DEB patients. The company is currently working with the FDA towards further research and possible approval for this application.
Read more →KRYSKrystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
Krystal Biotech, Inc. will present at the Guggenheim 6th Annual Biotechnology Conference on February 7-8, 2024, in New York. CEO Krish S. Krishnan is set to participate in a fireside chat and conduct investor meetings during the event. The webcast of the presentation will be available online. Krystal Biotech focuses on developing genetic medicines, including VYJUVEK®, which is FDA-approved for treating dystrophic epidermolysis bullosa.
Read more →KRYSKrystal Biotech Receives Permanent J-code (J3401) for VYJUVEK
Krystal Biotech, Inc. has announced that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent J-code (J3401) for its gene therapy product, VYJUVEK. This development, effective January 1, 2024, is expected to streamline reimbursement processes for healthcare providers administering the treatment. VYJUVEK is the first FDA-approved therapy for dystrophic epidermolysis bullosa (DEB), designed to deliver the COL7A1 gene to treat this rare and severe skin condition. The J-code is anticipated to facilitate improved access to this treatment for patients in need.
Read more →KRYSKrystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
Krystal Biotech has announced that its investigational therapy beremagene geperpavec-svdt (B-VEC) has been granted Orphan Drug Designation by the Japan Ministry of Health, Labour and Welfare. This designation aims to expedite the drug's development for dystrophic epidermolysis bullosa (DEB), a disease with significant unmet medical needs. The company plans to collaborate closely with MHLW to bring this important treatment to patients in Japan. The designation also includes various regulatory and financial incentives to support the drug's development.
Read more →KRYSKrystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced the validation of its Marketing Authorization Application for VYJUVEK by the European Medicines Agency (EMA). This application is aimed at treating dystrophic epidermolysis bullosa (DEB), potentially benefiting approximately 3,000 patients in the European Union. VYJUVEK has previously received Orphan Drug Designation and PRIME eligibility, reflecting its significance in addressing an unmet medical need in Deb patients. A decision from the EMA's Committee for Medicinal Products for Human Use (CHMP) is expected in the second half of 2024.
Read more →KRYS▼ -6.1%on this news
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
Krystal Biotech, Inc. announced its participation in the Stifel 2023 Healthcare Conference, where CEO Krish Krishnan will be involved in a fireside chat and investor meetings on November 15. The event highlights the company's commitment to engaging with investors as it focuses on the commercialization of genetic therapies. Krystal Biotech is known for its innovative approaches, including its FDA-approved gene therapy, VYJUVEK, for treating dystrophic epidermolysis bullosa. The company continues to develop multiple investigational therapies across various medical fields.
Read more →KRYS▼ -15%on this newsshared move
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
Krystal Biotech reported a strong third quarter for 2023, highlighting the success of its VYJUVEK product launch with $8.6 million in net revenues. The company advanced its clinical programs, completing Phase 1 trials for KB407 and beginning treatments for KB707. Additionally, an IND application for KB408 for AATD was cleared, allowing for forthcoming trials. Financially, Krystal closed the quarter with a robust balance sheet, holding nearly $600 million in cash reserves.
Read more →KRYS▼ -15%on this newsshared move
Nine Months Ended
Krystal Biotech has reported its financial results for the third quarter of 2023, highlighting a total of $8.6 million in net product revenue from VYJUVEK, a therapy for Dystrophic Epidermolysis Bullosa (DEB). The company has made significant progress in its clinical programs, including the completion of a Phase 1 trial for KB407 in patients with cystic fibrosis and the initiation of a trial for KB707, targeting solid tumor malignancies. Additionally, Krystal Biotech maintains a strong financial position with $598.6 million in cash and is on track to pursue further regulatory approvals and clinical advances in the coming year.
Read more →KRYSKrystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
Krystal Biotech, Inc. is set to report its third quarter financial results on November 6, 2023, before the U.S. markets open. Following the release, the company will hold an investor conference call at 8:30 am ET to provide insights into its financial performance and business developments. Krystal Biotech is known for its groundbreaking gene therapy, VYJUVEK®, and is advancing a diverse pipeline targeting several medical fields.
Read more →KRYSKrystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the Chardan 7th Annual Genetic Medicines Conference in New York on October 3. CEO Krish Krishnan will engage in a fireside chat and hold investor meetings. A webcast of the presentation will be accessible on the company's investor website, enhancing transparency and engagement with stakeholders. This event underscores the company's focus on advancing genetic medicines for diseases with high unmet medical needs.
Read more →KRYSKrystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
Krystal Biotech, Inc. announced that the FDA has cleared its Investigational New Drug Application for KB408, a gene therapy for alpha-1 antitrypsin deficiency (AATD). This approval allows the company to advance to clinical trials, specifically a Phase 1 study aimed at evaluating the safety and efficacy of KB408. The treatment uses a modified vector for delivering genes to lung cells and has been granted orphan drug designation, highlighting its significance in addressing a rare genetic condition with limited treatment options. The first patient is expected to be dosed in Q1 2024.
Read more →KRYSKrystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Krystal Biotech, Inc. has announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference to be held in New York. CEO Krish Krishnan will engage in a fireside chat and conduct investor meetings on September 12. The event aims to showcase the company's advancements in genetic medicines, particularly in addressing conditions with significant unmet medical needs.
Read more →KRYSKrystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Krystal Biotech, Inc. has announced that the U.S. FDA granted Orphan Drug Designation for its product KB408, aimed at treating alpha-1 antitrypsin deficiency (AATD). AATD leads to severe respiratory issues due to the deficiency of alpha-1 antitrypsin protein. KB408 is an inhaled formulation designed to deliver the SERPINA1 gene and address this unmet medical need. The company expresses optimism around KB408's preclinical results and looks forward to progressing toward patient dosing upon FDA clearance.
Read more →KRYS▲ +5.2%on this news
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
Krystal Biotech has successfully completed the sale of its Rare Pediatric Disease Priority Review Voucher for $100 million. This voucher was awarded by the FDA following the accelerated approval of VYJUVEKTM for treating dystrophic epidermolysis bullosa in patients aged six months and older. The voucher can expedite the review process for future marketing applications or be sold as practiced in the industry. The company continues to focus on its innovative genetic medicine portfolio addressing high unmet medical needs.
Read more →KRYS▼ -12.6%on this news
Six Months Ended
Krystal Biotech reported strong second quarter results, highlighted by FDA approval of VYJUVEK, the first topical gene therapy for dystrophic epidermolysis bullosa. The company observed rapid uptake of the therapy, with 121 Patient Start Forms in the first six weeks of launch. In addition, Krystal Biotech made significant progress in its clinical pipeline, including the first patient dosed in a cystic fibrosis trial and FDA acceptance of the KB707 IND with Fast Track Designation. Despite positive developments, the company reported net losses and rising administrative expenses.
Read more →KRYS▼ -12.6%on this news
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
Krystal Biotech announced its second quarter 2023 financial results, highlighting the recent approval of VYJUVEK for treating dystrophic epidermolysis bullosa (DEB) and an early positive response from patients. The company reported a solid cash position of $505.9 million and progress on its clinical pipeline, including the first patient dosed in its cystic fibrosis trial. Additionally, the FDA accepted the IND for KB707, marking a significant step in their oncology efforts. However, the company noted an increase in net losses compared to the previous year.
Read more →KRYSKrystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707 PITTSBURGH
Krystal Biotech has expanded its pipeline into oncology with the FDA's acceptance of the IND application for its lead candidate, KB707, aimed at treating solid tumors. This candidate utilizes a modified HSV-1 vector to deliver key immune-enhancing cytokines, IL-2 and IL-12, within the tumor environment. The company plans to initiate a Phase 1 study in late 2023, evaluating its safety and efficacy in patients. This strategic move highlights Krystal's focus on addressing unmet medical needs in cancer therapeutics.
Read more →KRYSKrystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
Krystal Biotech has announced the dosing of the first patient in its Phase 1 clinical trial for KB407 at the Cystic Fibrosis Institute of Chicago. The trial evaluates an innovative genetic medicine designed to address the symptoms of cystic fibrosis by delivering full-length copies of the CFTR gene directly to the lungs. This treatment is significant as it is mutation-agnostic, potentially benefiting all cystic fibrosis patients. The multicenter study aims to gather safety and efficacy data, with results anticipated in 2024.
Read more →KRYS▲ +22.4%on this news
Krystal Biotech Announces $160 Million Private Placement Equity Financing PITTSBURGH
Krystal Biotech has announced a successful private placement equity financing, raising approximately $160 million through the sale of nearly 1.73 million shares at $92.50 each. This financing, supported by key institutional investors, is aimed at funding the launch of VYJUVEK, a gene therapy approved for treating dystrophic epidermolysis bullosa, as well as advancing the company's pipeline through 2026. The transaction is set to close subject to customary closing conditions and includes plans to register the shares for resale with the SEC.
Read more →KRYS▲ +9.8%on this news· ran to +36% by day 3shared move
Updated Risk Factors Risks Related to Our Business We have limited experience as a commercial company and the sales, marketing, and distribution of VYJUVEK or any future approved products may be unsuccessful or less succ
Kryssos Holdings, under the ticker KRYS, has received FDA approval for its product VYJUVEK, initiating its commercial launch in the U.S. However, the company faces substantial challenges due to its lack of experience in the commercialization process. There are significant uncertainties surrounding the development of sales and marketing capabilities, which are essential for success. Additionally, the market for VYJUVEK may be smaller than projected, and potential discrepancies in patient populations could adversely affect future revenues and financial stability.
Read more →KRYS▲ +9.8%on this news· ran to +36% by day 3shared move
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech has received FDA approval for VYJUVEK™, a groundbreaking topical gene therapy aimed at treating dystrophic epidermolysis bullosa (DEB). This innovative therapy is the first of its kind that allows for repeated dosing to restore the missing COL7 protein, effectively promoting wound healing. The approval was supported by promising results from pivotal clinical trials that showcased significant improvements in wound recovery. VYJUVEK will be available in the U.S. in the third quarter of 2023, along with a personalized support program for patients and caregivers.
Read more →KRYSDocument Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights PDUFA date of
Krystal Biotech, Inc. announced its financial results for Q1 2023, highlighting a strong cash position of $355.5 million and operational progress towards the FDA approval of its gene therapy B-VEC. The company shared positive clinical data supporting the use of B-VEC for improving vision in patients with recessive dystrophic epidermolysis bullosa, demonstrating the potential for a broader application in ophthalmology. On the downside, the company reported a net loss of $45.3 million, reflecting increased financial pressures.
Read more →KRYSKrystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
PDUFA date of May 19, 2023 Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate Use Program Strong balance sheet, closing the quarter with $355.5
Read more →KRYSKrystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program Data presented at Asso
Krystal Biotech has presented promising clinical data on its topical therapy B-VEC for treating ocular complications in a patient with dystrophic epidermolysis bullosa (DEB). The data, shared at the ARVO 2023 Annual Meeting, indicates that B-VEC was well tolerated and resulted in significant improvements in visual acuity and corneal healing. The company plans to engage with regulatory authorities to explore broader uses of B-VEC in addressing ocular complications associated with DEB, which currently lacks FDA-approved treatments.
Read more →KRYS▲ +6.6%on this news
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH, April 13, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ
Read more →KRYSKrystal Biotech Appoints Catherine Mazzacco to Board of Directors
Krystal Biotech has appointed Catherine Mazzacco to its Board of Directors, highlighting her extensive background in the pharmaceutical and biotechnology sectors. The company's CEO, Krish S. Krishnan, expressed optimism about Mazzacco's contribution amid a pivotal phase for the company. Mazzacco aims to help steer the company's strategic objectives and enhance its preparedness for commercialization in the genetic rare diseases market.
Read more →KRYSKrystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the 43rd A
Read more →KRYSKrystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Krystal Biotech reported its financial results and operational progress for Q4 and the full year of 2022. The company highlighted a strong cash position of $383.8 million and announced a PDUFA date of May 19, 2023, for its B-VEC biologics application. Additionally, multiple clinical trials are set to commence in 2023, underpinning the company's growth ambitions. However, the financial report showed increasing losses and rising operational costs, alongside the need for modifications in its European marketing authorization application.
Read more →KRYSKrystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the European Commission has granted orphan
Read more →KRYS▼ -10.9%on this news
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration (FDA) notified the Company that based on manufacturing information submitted to the Agency on December
Read more →KRYSKrystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the BofA Se
Read more →KRYSKrystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercor
Read more →KRYS▲ +6.6%on this news
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
• Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023 • Notified of no Advisory Committee meeting or a need for Risk Evaluation and Mitigation Strategie
Read more →KRYSKrystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4. Kri
Read more →KRYSKrystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the European M
Read more →KRYSKrystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September
Read more →KRYSKrystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
Biologics License Application for B-VEC filed with the FDA on June 22, 2022 FDA accepts IND on KB407 for the treatment of Cystic Fibrosis Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments PITTSBURGH, Aug. 08, 2022 (GLOBE NE
Read more →KRYSKrystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redos
Read more →KRYSKrystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redos
Read more →KRYSKrystal Biotech to Present at William Blair Biotech Focus Conference 2022
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from July 12-13.
Read more →KRYS▲ +6.8%on this news
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-V
Read more →KRYSKrystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, Califo
Read more →KRYSKrystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational,
Read more →KRYS▼ -12.3%on this news
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing a
Read more →KRYSKrystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Hea
Read more →KRYSKrystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension
Read more →KRYSKrystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with p
Read more →KRYSThis presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (the "C
AAD GEM-3 Phase 3 Data Conference Call This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (the "Company"), including
Read more →KRYSKrystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editin
Read more →KRYSKrystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022 American Academy of Dermatology Annual Meeting, taki
Read more →KRYSKrystal Biotech Announces Settlement with PeriphaGen, Inc. PITTSBURGH
Krystal Biotech Announces Settlement with PeriphaGen, Inc. PITTSBURGH, March 15, 2022 Krystal Biotech, Inc., ( Krystal ) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. ( Peripha
Read more →KRYSKrystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022 Phase 1 trial of KB407 in cystic fibrosis patients in Australia expected to be
Read more →KRYS▲ +5.3%on this newsshared move
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Ca
Read more →KRYSKrystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board January 18, 2022 (GLOBE NEWSWIRE) Krystal Biotech, Inc., ( Krystal ) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today t
Read more →KRYS▼ -13.5%on this news
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common
Read more →KRYS▲ +121.7%on this newsshared move
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa - Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-mon
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa - Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete woun
Read more →KRYS▲ +121.7%on this newsshared move
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and cer
Read more →KRYSKrystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 Enrollment in Phase 1 proof-of-concept study (PEARL-1 stud
Read more →KRYSKrystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.
Read more →KRYSKrystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable
Read more →KRYSKrystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, f
Read more →KRYSKrystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 20
Read more →KRYSKrystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
- KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for
Read more →KRYSKrystal Biotech Appoints Laurent Goux as General Manager of Europe
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe. Mr. Goux has more than 20 years of global
Read more →KRYSKrystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”
Read more →KRYSKrystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conf
Read more →KRYSKrystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa ( DEB ) on track for 4Q21
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress PITTSBURGH, August 9, 2021 Krystal Biotech Inc., ( Krystal ) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and
Read more →KRYSJeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality - KB301 is designed to deliver a full-length human type III collagen transgene via intraderm
Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality - KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injection - Initial data from this efficacy cohort of
Read more →KRYSKrystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis - - New data include update from the fourth patient treated in the Phase 1/2 trial - - Repea
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis - New data include update from the fourth patient treated in the Phase 1/2 trial - Repeat topical KB105 dosing continues to be well tolerated with no
Read more →KRYSKrystal Biotech to Participate in Upcoming Investor Conferences
PITTSBURGH, June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman S
Read more →KRYSKrystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-ter
Read more →KRYSKrystal Biotech Appoints Andy Orth as Chief Commercial Officer
PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnolo
Read more →KRYSKrystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentat
Read more →KRYSKrystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment
Read more →KRYSKrystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH, April 19, 2021 (GLOBE NEWSWI
Read more →KRYSKrystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa (DEB). B
Read more →KRYSKrystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications - Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerabili
Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications - Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections - Dr. Bhushan Hardas M.D.,
Read more →KRYSKrystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. Today announced Positive Opinion from the European Me
Read more →KRYSKrystal Biotech to Present at the Cowen 41st Annual Health Care Conference
PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer will be participating in a fireside chat at the 4
Read more →KRYSKrystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock
PITTSBURGH, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common s
Read more →KRYSForward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Kr
The Leader in Redosable Gene Therapy Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (
Read more →KRYSKrystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors PITTSBURGH
Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors PITTSBURGH, January 4, 2021 Krystal Biotech Inc., ( Krystal ) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD
Read more →KRYSKrystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress - Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study o
Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars - Today announced additi
Read more →KRYSKrystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences
PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and
Read more →KRYSKrystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications
KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH, Aug. 25, 2020 (GL
Read more →KRYSKrystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis
PITTSBURGH, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the U.S. Food & Drug Administration (FDA) has
Read more →KRYSKrystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients Today announced enrollment of 1 st pat
Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients Today announced enrollment of 1st patient in Phase 2 clinical study evaluating KB105 in ARCI pa
Read more →KRYSKrystal Biotech to Present at the William Blair BioTech Conference
PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and
Read more →KRYSKrystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa
The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB) patients Top line data and BLA filing are anticipated in 2021; EMA aligned on pivotal study design and an MAA is anticipated
Read more →KRYSKrystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development
PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly creat
Read more →KRYSKrystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S. Krishnan, chairman and ch
Read more →KRYSKrystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously
Read more →KRYSKrystal Biotech Announces Proposed Public Offering of Common Stock
PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has commenced an underwrit
Read more →KRYSKrystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI) KB105 was well tolerated with no adverse events or
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI) KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM
Read more →KRYSIn Vitro Pharmacology of KB407, an HSV-1-Based Gene Therapy Vector, for the Treatment of Cystic Fibrosis ASGCT 2020 Court Freedman, Trevor Parry, Pooja Agarwal, Alexandra Collin de l Hortet, and Suma Krishnan
Pharmacology of KB407, an HSV-1-Based Gene Therapy Vector, for the Treatment of Cystic Fibrosis ASGCT 2020 Court Freedman, Trevor Parry, Pooja Agarwal, Alexandra Collin de l Hortet, and Suma Krishnan May 12, 2020 Krystal Biotech, Inc. Pittsburgh, PA, 15203 INTRODUCTION RESULTS (
Read more →KRYSKrystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be annou
Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) A
Read more →KRYSKrystal Biotech Reports 2019 Financial Results and Business Progress Phase 3 trial of B-VEC (Beremagene Geperpavec, previously KB103 ) to treat dystrophic epidermolysis bullosa ( DEB ) to start in 1H 2020 Interim results
Krystal Biotech Reports 2019 Financial Results and Business Progress Phase 3 trial of B-VEC (Beremagene Geperpavec, previously KB103 ) to treat dystrophic bullosa ( DEB ) to start in 1H 2020 Interim results on Phase 1/2 clinical study on KB105 to be announced in 1H 2020 Plann
Read more →KRYSKrystal Biotech Announces Change in Financial Leadership PITTSBURGH
Krystal Biotech Announces Change in Financial Leadership PITTSBURGH, Feb. 25, 2020 Krystal Biotech, Inc., ( Krystal ) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced t
Read more →KRYSKrystal Biotech to Present at the Cowen 40th Annual Healthcare Conference
PITTSBURGH, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility
PITTSBURGH, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the second commercial gene therapy facility in Findlay Township, Pennsylvania. The Findlay
Read more →KRYSKrystal Biotech Appoints Jennifer Chien as Chief Commercial Officer
PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial officer, effective January 20
Read more →KRYSKrystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference
PITTSBURGH, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotech Reports Third Quarter 2019 Financial and Operating Results Alignment with FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, B-VEC ) KB105 granted Fast Track Designation by th
Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results Alignment with FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, KB105 granted Fast Track Designation by the FDA Platform patent for delivering any effector to the skin gra
Read more →KRYSKrystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ( bercolagene telserpavec, B-VEC ) Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adve
Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ( bercolagene telserpavec, B-VEC ) PITTSBURGH, October 29, 2019 Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients su
Read more →KRYSKrystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis
PITTSBURGH, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued
Read more →KRYSKrystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chi
Read more →KRYSKrystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, announced the granting of a new patent for its lead prod
Read more →KRYSKrystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)
PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosoma
Read more →KRYSKrystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference
PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotech Reports Second Quarter 2019 Financial and Operating Results FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial ( GEM-2 ) of
Krystal Biotech Reports Second Quarter 2019 Financial and Operating Results FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial ( GEM-2 ) of KB103 Submitted an IND application to initiate a Phase 1
Read more →KRYSKrystal Biotech, Inc. Added to the Russell 2000 Index
PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000® Index, effective after the stock market close on June 28
Read more →KRYSKrystal Biotech Announces Positive Results from Phase 2 Clinical Trial ( GEM-2 study ) of KB103 and Receives Regenerative Medicine Advanced Therapy ( RMAT ) Designation from FDA for KB103 Safety data from all patients sh
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial ( GEM-2 study ) of KB103 and Receives Regenerative Medicine Advanced Therapy ( RMAT ) Designation from FDA for KB103 PITTSBURGH, June 24, 2019 Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company de
Read more →KRYSKrystal Biotech Announces Pricing of $100.0 Million Public Offering of Common Stock
PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the prev
Read more →KRYSKrystal Biotech Announces Proposed $100 Million Public Offering of Common Stock
PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has commenced an un
Read more →KRYSKrystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis KB105 is the second pipeline product based on the STAR-D platform and is part of a growing pipeline of gene therapy
Read more →KRYSKrystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference
PITTSBURGH, May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at the upc
Read more →KRYSKrystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update EMA grants PRIME eligibility for KB103 (bercolagene telserpavec) to treat dystrophic epidermolysis bullosa Krystal Biotech announ
Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update EMA grants PRIME eligibility for KB103 (bercolagene telserpavec) to treat dystrophic epidermolysis bullosa Krystal Biotech announces five presentations of clinical and preclinical data at
Read more →KRYSKrystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting
PITTSBURGH, April 29, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and preclinical d
Read more →KRYSKrystal Biotech Reports 2018 Financial Results and Business Progress Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1
Krystal Biotech Reports 2018 Financial Results and Business Progress Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and commerci
Read more →KRYSKrystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters
New facility expected to meet all clinical and commercial development needs of lead program KB103 A second, larger cGMP facility expected to be completed in 2020 to meet all anticipated future pipeline production requirements PITTSBURGH, March 06, 2019 (GLOBE NEWSWIRE) -- Kryst
Read more →KRYSKrystal Strengthens Board of Directors with Appointment of Julian S. Gangolli PITTSBURGH
Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli PITTSBURGH, March 4, 2019 Krystal Biotech Inc., (Krystal) (NASDAQ: KRYS), a gene therapy company developing off-the-shelf treatments for rare dermatological diseases, announced that Julian S. Gangolli
Read more →KRYSKrystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference
PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chi
Read more →KRYSKrystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference
PITTSBURGH, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chi
Read more →KRYSKrystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
PITTSBURGH, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-
Read more →KRYSKrystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that four patients have been dosed in the GEM-Pha
Read more →KRYSKrystal Biotech to Present at Evercore ISI HealthCONx
PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis
Read more →KRYSKrystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Over-Allotment Option PITTSBURGH
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Over-Allotment Option PITTSBURGH, October 23, 2018 Krystal Biotech, Inc. (Nasdaq:KRYS) (the Company ), a gene therapy company dedicated to developing and commercializing n
Read more →KRYSKrystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
PITTSBURGH, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the prev
Read more →KRYSKrystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock PITTSBURGH
Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock PITTSBURGH, October 17, 2018 Krystal Biotech, Inc. (Nasdaq:KRYS) (the Company ), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering fr
Read more →KRYSKrystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103 KB103 is Krystal s first off-the-shelf , topical, gene therapy candidate to treat patients suffering from Dystr
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103 KB103 is Krystal s first off-the-shelf , topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa. Results on 2 patients met al
Read more →KRYSKrystal Biotech to Present at Chardan Annual Genetic Medicines Conference
PITTSBURGH, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotech to Present at 2018 Cell & Gene Meeting on the Mesa
PITTSBURGH, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Suma Krishnan, founder and chief ope
Read more →KRYSKrystal Biotech to Present at Upcoming Cantor Fitzgerald and Ladenburg Thalmann Conferences
PITTSBURGH, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chi
Read more →KRYSKrystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences
PITTSBURGH, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chie
Read more →KRYSKrystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis
KB105 is Krystal’s second "off-the-shelf" topical gene therapy candidate to receive Rare Pediatric Disease Designation for treating debilitating skin diseases PITTSBURGH, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to
Read more →KRYSKrystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners
PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purch
Read more →KRYSKRYSTAL BIOTECH, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the Agreement ) is made as of
KRYSTAL BIOTECH, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the Agreement ) is made as of August 16, 2018 (the Effective Date ), by and among Krystal Biotech, Inc., a Delaware corporation (the Company ), and the purchasers whose names and addresses are set fo
Read more →KRYSKrystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis
PITTSBURGH, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food & Drug Administration (FD
Read more →KRYSKrystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update
First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (NASDAQ:KRYS), a gene therapy company advancing “off-the-
Read more →KRYSKrystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018
PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s lead product candi
Read more →KRYSKrystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, May 10, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that the first patient has been dosed in the Phase
Read more →KRYSKrystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
Lead product candidate, KB103, shown to successfully transfer COL7A1 gene and to correct recessive dystrophic epidermolysis bullosa (RDEB) PITTSBURGH, May 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and
Read more →KRYSKrystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update IND for KB103 to treat dystrophic epidermolysis bullosa (DEB) cleared by FDA. Patient enrollment in Phase 1/2 study of KB103 to b
Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update IND for KB103 to treat dystrophic epidermolysis bullosa (DEB) cleared by FDA. Patient enrollment in Phase 1/2 study of KB103 to begin in May 2018 at Stanford University Krystal Biotech s
Read more →KRYSKrystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
KB103 is the first-ever herpes simplex virus (HSV-1) based topical gene therapy candidate engineered to produce human collagen protein to treat dystrophic epidermolysis bullosa (DEB) The planned Phase 1/2 KB103 single site clinical study is expected to start in May 2018 at Stanf
Read more →KRYSKrystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
KB103 represents the first investigational HSV-1 based gene therapy for the severe skin disorder dystrophic epidermolysis bullosa to receive this designation KB103 previously received Orphan Drug Designation for DEB from U.S. FDA PITTSBURGH, April 19, 2018 (GLOBE NEWSWIRE) -- K
Read more →KRYSKrystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
PITTSBURGH, April 18, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s proprietary technology, the Skin TARgeted
Read more →KRYSKrystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
KB103 is an internally generated modified HSV-1 based gene therapy candidate engineered with a COL7A1 gene construct to treat Dystrophic Epidermolysis Bullosa (DEB) Therapeutic candidate formulated into a topical gel for direct application onto skin PITTSBURGH, March 27, 2018 (
Read more →KRYSKrystal Biotech Reports 2017 Financial Results and Business Progress
IND for KB103 to treat Dystrophic Epidermolysis Bullosa (DEB) to be filed in March 2018 IND for KB105 to treat Lamellar Ichthyosis to be filed in Q4 2018 Company was granted composition of matter and method of use patent by USPTO in GMP facility for production of KB103 and pip
Read more →KRYSKrystal Biotech, Inc. to Present at the 30th Annual ROTH Conference
PITTSBURGH, March 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan, Chief Executive Officer, will present a corporate overview and busine
Read more →KRYSKrystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases
PITTSBURGH, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that the United States Patent Office (USPTO) has granted U.S. Patent No. 9,877,990 which co
Read more →KRYSKrystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results PITTSBURGH, Pa.
Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results PITTSBURGH, Pa., November 13, 2017 Krystal Biotech, Inc. (NASDAQ: KRYS), a gene therapy company advancing off-the-shelf, topical and intra-dermal treatments
Read more →KRYSKrystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
PITTSBURGH, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food & Drug Administratio
Read more →KRYSKrystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research Foundation
PITTSBURGH, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has received an equity-based award t
Read more →KRYSKrystal Biotech Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PITTSBURGH, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the closing of its initial publ
Read more →KRYSKrystal Biotech Announces Presentation of KB103 Data at EB2017 - The 5th World Conference of EB Research
PITTSBURGH, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”)(Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced a presentation of preclinical da
Read more →KRYSKrystal Biotech Announces Pricing of Upsized Initial Public Offering Pittsburgh, Pennsylvania
Krystal Biotech Announces Pricing of Upsized Initial Public Offering Pittsburgh, Pennsylvania September 19, 2017 Krystal Biotech, Inc. ( Krystal ), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological dis
Read more →Competitive Position
How KRYS ranks across every disease it competes inCompetitive Position is a premium feature
See how KRYS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial